Therefore, targeting EREG/EGFR in the TME may provide therapeutic options for patients with NSCLC, particularly a subset of NSCLC with driver mutation or resistance to EGFR-TKIs, and patients with CRC with wild-type KRAS expression. Here, EREG is linked to colorectal carcinoma.